Consun Pharmaceutical Group (1681) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Consun Pharmaceutical Group stock HK$33.33, price HK$15.75, upside +111.6%, quality 81 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Consun Pharmaceutical Group
1681 · HKCheap (53% below fair value), strong company and rising price: meets all 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range HK$2.16 – HK$18.30 · fair‑value band HK$20.17 – HK$43.33 · the HK$15.75 price screens below the HK$33.33 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Consun Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical.
Show moreShow less
The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products.
It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal.
In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines.
Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.
Stock analysis
Consun Pharmaceutical Group (1681) currently trades at HK$15.75, while our model-based Fair Value estimate is HK$33.33, implying the stock looks roughly 53% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$35.82 per share, and 21 of the 26 models we run sit above the HK$15.75 price.
Bear case: the Asset-Based group reads lowest at HK$3.83, and 5 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: HK$20.17 (bear) to HK$43.33 (bull), the price of HK$15.75 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 81/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Consun Pharmaceutical Group reported revenue of 3.4B CNY in FY2025 versus 2.0B CNY in FY2021, a compound +13.7%/yr. Reported net income was 1.1B CNY in FY2025, compounding +16.3%/yr from FY2021.
Key figures
Market cap HK$13.3B (≈ $1.7B) Small · P/E ratio 10.0 · P/S ratio 3.15 · Dividend yield 4.3% · Net margin 31.5% · Return on equity 24.4% · Return on assets (EBIT) 16.9% (5-year average) · Operating margin 37.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 88 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 112%, 1681 screens cheaper than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 1681, get fair value alerts →
Compare Consun Pharmaceutical Group with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Quality Score by industry
- Return on equity by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs 1681 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs 1681 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs 1681 |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs 1681 |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs 1681 |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs 1681 |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs 1681 |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs 1681 |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs 1681 |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs 1681 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Consun Pharmaceutical Group (1681) overvalued or undervalued?
What is the fair value of 1681?
What is the quality score of 1681?
What is the price target for Consun Pharmaceutical Group (1681)?
What is the Consun Pharmaceutical Group stock forecast for 2026?
What is the revenue of Consun Pharmaceutical Group (1681)?
Does Consun Pharmaceutical Group pay a dividend?
How much is the dividend of Consun Pharmaceutical Group (1681) and when is the ex-dividend date?
What growth is priced into Consun Pharmaceutical Group (1681)?
What discount rate (WACC) does the fair value of 1681 use?
What is a reverse DCF?
How much growth has Consun Pharmaceutical Group (1681) delivered so far?
How fast is the sector of Consun Pharmaceutical Group (1681) growing?
What is the free cash flow yield of Consun Pharmaceutical Group (1681)?
What is the intrinsic value of Consun Pharmaceutical Group (1681)?
Is Consun Pharmaceutical Group stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 1681?
How much is Consun Pharmaceutical Group worth?
What do the bullish and bearish scenarios say about 1681?
What is the P/E ratio of 1681?
How solid is the balance sheet of Consun Pharmaceutical Group (1681)?
How far is 1681 from its 52-week high?
Which stocks are comparable to Consun Pharmaceutical Group?
Is Consun Pharmaceutical Group stock attractive at the current price?
How is the fair value of 1681 calculated?
Is it still worth investing in stocks now?
What is the share price of Consun Pharmaceutical Group (1681)?
What should I pay attention to with Consun Pharmaceutical Group right now?
Where does the earnings growth of Consun Pharmaceutical Group (1681) come from?
Key figures of Consun Pharmaceutical Group
How large is the market capitalisation of Consun Pharmaceutical Group (1681)?
What is the P/S ratio of Consun Pharmaceutical Group (1681)?
What is the dividend yield of Consun Pharmaceutical Group (1681)?
What is the net margin of Consun Pharmaceutical Group (1681)?
What is the return on equity of Consun Pharmaceutical Group (1681)?
What is the EBIT return on assets of Consun Pharmaceutical Group (1681)?
What is the operating margin of Consun Pharmaceutical Group (1681)?
How fast is revenue growing at Consun Pharmaceutical Group (1681)?
How fast are earnings growing at Consun Pharmaceutical Group (1681)?
How much net cash does Consun Pharmaceutical Group (1681) hold?
Watch Consun Pharmaceutical Group in the live analysis
One click puts Consun Pharmaceutical Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.